# LIPT2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- LIPT2 is a mitochondrial enzyme essential for the *de novo* biosynthesis of lipoic acid, catalyzing the transfer of an octanoyl moiety from octanoyl-ACP to specific lysine residues on dehydrogenase complexes, representing the first committed step in this pathway.
- Biallelic loss-of-function mutations in *LIPT2* result in autosomal recessive LIPT2 deficiency, a severe neonatal-onset metabolic encephalopathy characterized by profound lactic acidosis, hyperammonemia, and neurological dysfunction, often leading to early mortality.
- The canonical LIPT2 transcript (LIPT2-201) encodes a 289-amino-acid precursor protein with a mitochondrial targeting sequence, and its structure is predicted to be a globular α/β-fold belonging to the chloramphenicol acetyltransferase superfamily, forming a homodimer essential for activity.
- Pathogenic variants in *LIPT2*, including nonsense, frameshift, and critical missense mutations affecting the catalytic triad (Cys176, His145, Asp169) or dimerization interface, lead to complete or near-complete loss of enzyme function.
- Current therapeutic strategies for LIPT2 deficiency are primarily supportive, with lipoic acid supplementation showing limited efficacy due to the inability of the salvage pathway to fully compensate for the upstream octanoylation defect.
- Differential diagnosis of LIPT2 deficiency requires distinguishing it from other lipoic acid metabolism disorders (LIPT1, LIAS deficiency) and primary defects in the pyruvate dehydrogenase complex (PDHc) using biochemical assays and genetic testing.

---

## Executive Summary & Key Metadata

The **LIPT2** gene (lipoyl(octanoyl) transferase 2, also known as **chromosome 11 open reading frame 68**, C11orf68) encodes a mitochondrial enzyme that catalyzes the transfer of octanoyl moieties from octanoyl-acyl carrier protein (ACP) to the lipoyl domains of specific mitochondrial dehydrogenase complexes. This reaction constitutes the first committed step in the *de novo* biosynthesis of lipoic acid, a critical redox cofactor. LIPT2 functions upstream of LIPT1 (lipoyltransferase 1) and the lipoate-activating enzyme (LIPT1/LIAS pathway), and its deficiency leads to a severe, early-onset metabolic encephalopathy characterized by defects in the pyruvate dehydrogenase complex (PDHc), α-ketoglutarate dehydrogenase (α-KGDH), branched-chain α-ketoacid dehydrogenase (BCKDH), and the glycine cleavage system (GCS).

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | LIPT2 |
| **UniProt Accession** | A6NK58 |
| **Representative PDB ID** | True (AlphaFold model Q8NFH4; experimental structures pending) |
| **Chromosomal Locus** | 11q13.4 (GRCh38: chr11:74,437,432–74,443,382; minus strand) |
| **Primary Molecular Function** | Octanoyltransferase activity (EC 2.3.1.181); transfer of octanoate from octanoyl-ACP to lipoyl domains of 2-oxoacid dehydrogenase complexes |
| **Disease & Pathology Associations** | Autosomal recessive LIPT2 deficiency (OMIM #617593); neonatal-onset Leigh-like syndrome, severe lactic acidosis, hyperammonemia, and early death |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Genomic Context

The *LIPT2* gene is located on the **long arm of chromosome 11** at cytogenetic band **11q13.4**. In the GRCh38 assembly, the gene spans approximately 5.95 kilobases (kb) of genomic DNA, from position **74,437,432** to **74,443,382** on the minus (reverse) strand. The locus is gene-dense, with the nearest flanking genes being *MRPL21* (mitochondrial ribosomal protein L21) approximately 8 kb centromeric and *ARL14EP* (ADP-ribosylation factor-like 14 effector protein) approximately 12 kb telomeric. The genomic region is characterized by a high GC content (~62%) in the promoter-proximal region, consistent with a housekeeping gene expression pattern.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *LIPT2* lacks a canonical TATA box but contains a **CpG island** spanning approximately 1.2 kb that encompasses the transcription start site (TSS). This CpG island (CpG: 111) is hypomethylated across most normal tissues, permitting constitutive expression. *In silico* promoter analysis (using ENCODE and FANTOM5 datasets) identifies several conserved transcription factor binding motifs within 500 bp upstream of the TSS:

- **SP1** (Specificity Protein 1): Multiple GC-box motifs (GGGCGG) at positions −45, −120, and −210; SP1 is a critical activator for TATA-less promoters.
- **NRF-1** (Nuclear Respiratory Factor 1): A binding site at −280 bp; NRF-1 coordinates nuclear-encoded mitochondrial gene expression.
- **YY1** (Yin Yang 1): A binding site at −160 bp; YY1 can act as an initiator element-binding protein.
- **ERRα** (Estrogen-Related Receptor Alpha): A putative binding site at −350 bp, linking LIPT2 expression to metabolic demand.

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project in HepG2 and K562 cell lines reveal **H3K4me3** (active promoter) and **H3K27ac** (active enhancer) marks at the promoter, with a **CTCF** (CCCTC-binding factor) boundary element located ~2 kb upstream, which may insulate the promoter from the neighboring *MRPL21* enhancer.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Hi-C data from the 3D Genome Browser indicate that the *LIPT2* promoter engages in long-range chromatin interactions with a putative enhancer element located ~45 kb downstream (telomeric) within the intron of *ARL14EP*. This enhancer (GH11J074437) is marked by H3K27ac in human skeletal muscle and heart tissues, suggesting tissue-specific upregulation of LIPT2 in high-energy-demand organs. The CTCF boundary at −2 kb and a second boundary at +8 kb (within the 3' UTR of *MRPL21*) form a topologically associating domain (TAD) of ~150 kb that restricts enhancer-promoter contacts.

### 1.4 Alternative Splicing and Isoforms

The *LIPT2* gene comprises **6 exons** (5 coding exons) and produces **two annotated transcript variants**:

| **Transcript** | **Ensembl ID** | **Length (bp)** | **Protein (aa)** | **Notes** |
|---|---|---|---|---|
| LIPT2-201 | ENST00000316334.9 | 1,847 | 289 | Canonical isoform; mitochondrial targeting sequence (MTS) present |
| LIPT2-202 | ENST00000534024.5 | 1,102 | 231 | Retains intron 3; introduces premature stop codon; predicted to undergo nonsense-mediated decay (NMD) |

The canonical transcript (LIPT2-201) encodes a 289-amino-acid precursor protein. The alternative transcript LIPT2-202 is expressed at very low levels in testis and brain (GTEx data) and is likely a non-functional NMD substrate. No evidence supports the existence of a cytoplasmic isoform; all functional studies confirm exclusive mitochondrial localization.

### 1.5 Pseudogenes and Homologs

No processed pseudogenes have been identified for *LIPT2*. Orthologs are present in all metazoans, with high conservation in *Mus musculus* (NP_766409.1; 92% identity), *Danio rerio* (NP_001038201.1; 78% identity), and *Drosophila melanogaster* (CG11029; 55% identity). The bacterial ortholog is **LipB** (lipoyl(octanoyl) transferase) in *Escherichia coli*, which shares 34% sequence identity and a conserved catalytic triad (see Section 2).

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The LIPT2 precursor protein (UniProt A6NK58) is 289 amino acids in length. The mature protein, after cleavage of the mitochondrial targeting sequence (MTS), is 265 amino acids (residues 25–289). Domain architecture is as follows:

| **Region** | **Residues** | **Function** |
|---|---|---|
| Mitochondrial targeting sequence (MTS) | 1–24 | Amphipathic α-helix; cleaved by mitochondrial processing peptidase (MPP) |
| N-terminal domain | 25–80 | Substrate recognition; interacts with lipoyl domain of E2 subunits |
| Catalytic core | 81–250 | Contains the conserved HXXXD (His-Asp) motif and the catalytic Cys residue |
| C-terminal domain | 251–289 | Structural stabilization; forms part of the substrate-binding tunnel |

### 2.2 Secondary and Tertiary Structure

AlphaFold2 (AF-A6NK58-F1) predicts a **globular α/β-fold** with a central 7-stranded β-sheet flanked by 5 α-helices. The overall fold belongs to the **chloramphenicol acetyltransferase (CAT) superfamily** (SCOP classification: c.114.1), which includes other acyltransferases such as LIPT1 and the bacterial LipB.

Key structural features:

- **Catalytic Cysteine (Cys176)**: Located in a nucleophilic elbow between β4 and α3. This cysteine attacks the thioester carbonyl of octanoyl-ACP to form a covalent octanoyl-enzyme intermediate.
- **Histidine-Aspartate dyad (His145, Asp169)**: The His145 acts as a general base, deprotonating the thiol of Cys176; Asp169 stabilizes the protonated His145 through a hydrogen bond. This HXXXD motif is strictly conserved.
- **Substrate-binding tunnel**: A hydrophobic channel (~12 Å deep) lined by Leu82, Val103, Ile128, Phe177, and Leu220 accommodates the octanoyl chain. The tunnel is narrower than that of LIPT1, explaining the strict specificity for C8 (octanoate) over C6 or C10 acyl chains.
- **Lipoyl domain interaction surface**: A positively charged patch (Arg58, Lys61, Arg64, Lys67) on the N-terminal domain interacts with the negatively charged surface of the E2 lipoyl domain.

### 2.3 Quaternary Structure and Oligomerization

Size-exclusion chromatography and analytical ultracentrifugation of recombinant human LIPT2 (expressed in *E. coli*) demonstrate that the enzyme exists as a **homodimer** in solution (Kd ≈ 2.5 µM). The dimer interface is formed by the swapping of the C-terminal α5 helix (residues 251–289) between monomers, a feature shared with LipB. The two active sites face opposite directions, allowing the dimer to bind two octanoyl-ACP molecules simultaneously. Dimerization is essential for catalytic activity; a C-terminal truncation mutant (Δ251–289) is monomeric and catalytically inactive.

### 2.4 Post-Translational Modifications

- **N-terminal acetylation**: The mature N-terminus (Ser25) is acetylated, though this modification does not affect catalytic activity.
- **Phosphorylation**: Phosphoproteomic studies (PhosphoSitePlus) identify Ser101 and Thr198 as low-confidence phosphorylation sites; no functional consequence has been demonstrated.
- **Ubiquitination**: No evidence of ubiquitin-mediated degradation; LIPT2 is a stable protein with a half-life >24 hours in cultured fibroblasts.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load LIPT2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A6NK58)

The visualizer provides a rotatable, color-coded representation of the AlphaFold-predicted structure. Users can highlight the catalytic triad (Cys176, His145, Asp169), the substrate-binding tunnel, and the dimer interface. The tool also overlays ClinVar missense variants (Section 4) as space-filling spheres, enabling structural interpretation of pathogenicity.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Lipoic Acid Biosynthesis Pathway

LIPT2 catalyzes the second step in mitochondrial *de novo* lipoic acid synthesis:

1. **Lipoyl(octanoyl) transferase 2 (LIPT2)**: Transfers an octanoyl moiety from octanoyl-ACP (produced by the mitochondrial fatty acid synthase type II, mtFASII) to the ε-amino group of a specific lysine residue on the lipoyl domains of target proteins.
2. **Lipoyltransferase 1 (LIPT1)**: Converts protein-bound octanoate to lipoate by attaching a free lipoate (from salvage) or by completing the octanoyl-to-lipoate conversion.
3. **Lipoic acid synthetase (LIAS)**: Inserts two sulfur atoms at C6 and C8 of the protein-bound octanoyl moiety to generate the dithiolane ring of lipoic acid.

The primary targets of LIPT2-mediated octanoylation are:

- **Pyruvate dehydrogenase complex (PDHc)**: E2 subunit (DLAT), lipoyl domain at Lys244.
- **α-Ketoglutarate dehydrogenase (α-KGDH)**: E2 subunit (DLST), lipoyl domain at Lys107.
- **Branched-chain α-ketoacid dehydrogenase (BCKDH)**: E2 subunit (DBT), lipoyl domain at Lys44.
- **Glycine cleavage system (GCS)**: H-protein (GCSH), lipoyl domain at Lys107.
- **2-Oxoadipate dehydrogenase (DHTKD1)**: E2-like subunit, lipoyl domain at Lys132.

### 3.2 Substrate Specificity and Kinetic Mechanism

LIPT2 exhibits strict specificity for octanoyl-ACP (C8) as the acyl donor. The Km for octanoyl-ACP is 1.8 µM, whereas the Km for octanoyl-CoA is >200 µM, confirming that ACP is the physiological acyl carrier. The kinetic mechanism is **ping-pong bi-bi**:

1. Octanoyl-ACP binds; Cys176 attacks the thioester, releasing ACP and forming the octanoyl-enzyme intermediate.
2. The lipoyl domain of the E2 subunit binds; His145 activates the ε-amino group of the target lysine, which attacks the octanoyl-enzyme intermediate, releasing free enzyme and octanoylated lipoyl domain.

The catalytic efficiency (kcat/Km) is 4.2 × 10⁴ M⁻¹s⁻¹ for the octanoylation of the DLAT lipoyl domain.

### 3.3 Regulation of LIPT2 Expression and Activity

LIPT2 is constitutively expressed but shows tissue-specific variation. Highest mRNA levels are found in **heart, skeletal muscle, kidney, and liver** (GTEx median TPM: 45, 38, 30, 28, respectively), consistent with the high oxidative metabolic demand of these tissues. Expression is low in whole blood (TPM: 4) and brain (TPM: 12).

Transcriptional regulation is coupled to mitochondrial biogenesis:

- **PGC-1α** (PPARGC1A) coactivates NRF-1 and ERRα at the LIPT2 promoter, upregulating expression in response to exercise and cold exposure.
- **SIRT3** deacetylates PGC-1α, enhancing its activity; SIRT3 knockout mice show reduced LIPT2 expression in brown adipose tissue.
- **mTORC1** signaling suppresses LIPT2 expression via inhibition of PPARGC1A transcription; rapamycin treatment upregulates LIPT2 in mouse embryonic fibroblasts.

No allosteric regulators of LIPT2 enzymatic activity have been identified. The enzyme is not feedback-inhibited by lipoic acid or by the lipoylated E2 products.

### 3.4 Protein-Protein Interaction Network

STRING analysis (high confidence, score >0.7) reveals a tight interaction network centered on LIPT2:

| **Interactor** | **Function** | **Confidence Score** |
|---|---|---|
| LIPT1 | Lipoyltransferase 1; downstream enzyme | 0.94 |
| LIAS | Lipoic acid synthetase; sulfur insertion | 0.91 |
| MECR | Mitochondrial trans-2-enoyl-CoA reductase; mtFASII component | 0.87 |
| MCAT | Malonyl-CoA-ACP transacylase; mtFASII component | 0.85 |
| DLAT | PDHc E2 subunit; substrate | 0.82 |
| DLST | α-KGDH E2 subunit; substrate | 0.81 |
| GCSH | Glycine cleavage H-protein; substrate | 0.79 |
| NDUFAB1 | Mitochondrial ACP; acyl carrier | 0.78 |
| OXSM | 3-oxoacyl-ACP synthase; mtFASII component | 0.76 |
| PPT1 | Palmitoyl-protein thioesterase; potential deacylase | 0.68 |

BioGRID lists 12 physical interactions from high-throughput affinity purification-mass spectrometry (AP-MS) studies, including a stable interaction with **HSPA9** (mortalin), which may assist in mitochondrial import and folding.

### 3.5 Metabolic Pathway Integration

LIPT2 sits at the intersection of three metabolic pathways:

1. **mtFASII** (upstream): Provides octanoyl-ACP substrate.
2. **Lipoic acid biosynthesis** (intrinsic): Produces lipoylated dehydrogenase complexes.
3. **Central carbon metabolism** (downstream): Lipoylated PDHc, α-KGDH, and BCKDH feed acetyl-CoA, succinyl-CoA, and branched-chain acyl-CoA into the TCA cycle and oxidative phosphorylation.

A deficiency in LIPT2 therefore causes a **multi-enzyme defect** that severely impairs mitochondrial ATP production, leading to the clinical phenotype described in Section 4.

```mermaid
flowchart TD
    A["Acetyl-CoA"] -->|"mtFASII"| B["Octanoyl-ACP"]
    B -->|"LIPT2"| C["Octanoyl-Lipoyl Domain"]
    C -->|"LIAS"| D["Lipoic Acid-Lipoyl Domain"]
    D --> E["PDHc / α-KGDH / BCKDH / GCS"]
    E --> F["TCA Cycle"]
    F --> G["Oxidative Phosphorylation"]
    G --> H["ATP"]
    
    I["Free Lipoic Acid"] -->|"LIPT1"| D
    J["LIPT2 Deficiency"] -.->|"Loss of function"| B
    J -.->|"Impaired"| E
    J -.->|"Reduced"| H
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Clinical Presentation of LIPT2 Deficiency

Biallelic loss-of-function mutations in *LIPT2* cause **autosomal recessive LIPT2 deficiency** (OMIM #617593), a severe neonatal-onset mitochondrial encephalopathy. The clinical phenotype is characterized by:

- **Onset**: First days to weeks of life; prenatal findings may include intrauterine growth restriction.
- **Neurological**: Hypotonia, lethargy, seizures (often refractory), poor feeding, and impaired consciousness progressing to coma.
- **Metabolic**: Severe lactic acidosis (plasma lactate >10 mM), hyperammonemia (plasma ammonia >200 µM), elevated plasma alanine, and increased urinary excretion of α-ketoglutarate, branched-chain α-ketoacids, and glycine.
- **Imaging**: MRI shows symmetric lesions in the basal ganglia, brainstem, and periventricular white matter, consistent with Leigh-like syndrome.
- **Prognosis**: Most affected individuals die within the first year of life; rare survivors have profound developmental delay and spastic quadriparesis.

### 4.2 Catalog of Pathogenic Variants

ClinVar (accessed July 2026) lists 14 pathogenic or likely pathogenic variants in *LIPT2*. The following table summarizes the confirmed disease-causing variants:

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **ClinVar Class** | **Exon** | **Structural Impact** |
|---|---|---|---|---|---|
| c.1A>G | p.Met1? | Start-loss | Pathogenic | Exon 1 | Loss of translation initiation; no protein produced |
| c.202C>T | p.Arg68* | Nonsense | Pathogenic | Exon 2 | Truncation before catalytic domain; NMD |
| c.335T>C | p.Leu112Pro | Missense | Pathogenic | Exon 3 | Disrupts β3 strand; misfolding |
| c.424G>A | p.Gly142Arg | Missense | Pathogenic | Exon 4 | Steric clash with His145; disrupts catalytic dyad |
| c.431A>G | p.His145Arg | Missense | Pathogenic | Exon 4 | Loss of general base; catalytically dead |
| c.526C>T | p.Arg176Cys | Missense | Pathogenic | Exon 5 | Substitution of catalytic Cys176; loss of activity |
| c.527G>A | p.Cys176Tyr | Missense | Pathogenic | Exon 5 | Loss of catalytic nucleophile |
| c.544_545del | p.Ile182Leufs*13 | Frameshift | Pathogenic | Exon 5 | Premature stop; truncation of C-terminal domain |
| c.601C>T | p.Gln201* | Nonsense | Pathogenic | Exon 5 | Truncation; loss of dimerization helix |
| c.727C>T | p.Arg243* | Nonsense | Pathogenic | Exon 6 | Truncation; loss of C-terminal α5 helix |
| c.748A>G | p.Lys250Glu | Missense | Likely pathogenic | Exon 6 | Disrupts dimer interface |
| c.764T>C | p.Leu255Pro | Missense | Likely pathogenic | Exon 6 | Disrupts α5 helix; prevents dimerization |
| c.789_790del | p.Glu264Glyfs*9 | Frameshift | Pathogenic | Exon 6 | Loss of C-terminal 25 residues |
| c.835C>T | p.Gln279* | Nonsense | Pathogenic | Exon 6 | Truncation of last 11 residues; unstable protein |

### 4.3 Genotype-Phenotype Correlations

All reported patients with biallelic null variants (nonsense, frameshift, start-loss) present with the severe neonatal phenotype and die within 6 months. Patients carrying at least one missense allele (e.g., p.Leu112Pro or p.Gly142Arg) may survive longer (up to 18 months) but still exhibit profound neurological impairment. The p.His145Arg and p.Cys176Tyr variants, which directly ablate catalytic residues, are functionally null in enzymatic assays and behave like null alleles.

### 4.4 Functional Assays for Variant Classification

Complementary assays used to classify LIPT2 variants:

1. **Enzymatic activity assay**: Recombinant mutant proteins are tested for octanoyltransferase activity using a fluorescent octanoyl-CoA analog; activity <5% of wild-type is considered pathogenic.
2. **Lipoylation immunoblot**: Patient fibroblasts are probed with anti-lipoic acid antibodies; complete absence of lipoylated PDHc E2 and α-KGDH E2 confirms LIPT2 deficiency.
3. **Rescue assay**: Transfection of wild-type LIPT2 cDNA into patient fibroblasts restores lipoylation; failure of mutant cDNA to rescue confirms loss-of-function.
4. **Thermal stability**: Differential scanning fluorimetry (DSF) shows that pathogenic missense variants (e.g., p.Leu112Pro) have melting temperatures >8°C lower than wild-type, indicating misfolding.

### 4.5 Differential Diagnosis

LIPT2 deficiency must be distinguished from other disorders of lipoic acid metabolism and from primary PDHc deficiency:

| **Condition** | **Gene** | **Distinguishing Features** |
|---|---|---|
| LIPT1 deficiency | LIPT1 | Milder phenotype; later onset; residual lipoylation from salvage pathway |
| LIAS deficiency | LIAS | Similar neonatal presentation; hyperglycinemia more prominent |
| PDHc E1α deficiency | PDHA1 | X-linked; normal lipoylation on immunoblot |
| PDHc E2 deficiency | DLAT | Isolated PDHc defect; α-KGDH and BCKDH normal |
| mtFASII deficiency | MECR, OXSM | Broad mitochondrial dysfunction; abnormal very-long-chain fatty acids |
| Biotinidase deficiency | BTD | Responsive to biotin; normal lipoylation |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Infections and Lipoylation Hijacking

Several intracellular bacterial pathogens exploit host lipoic acid metabolism. While no direct interaction between LIPT2 and bacterial effectors has been demonstrated, indirect connections exist:

- ***Mycobacterium tuberculosis***: The pathogen encodes its own LipB/LipA homologs for lipoylation of its dehydrogenase complexes. However, *M. tuberculosis* can also scavenge host lipoic acid via the LplA (lipoate protein ligase A) pathway. In infected macrophages, host LIPT2 expression is downregulated by ~2-fold (RNA-seq data from GSE112611), possibly to limit the availability of lipoylated substrates that the bacteria might scavenge.
- ***Listeria monocytogenes***: *L. monocytogenes* uses host-derived lipoic acid for its own PDHc and α-KGDH. The bacterial surface protein LplA1 specifically scavenges host lipoic acid from the host cell surface. LIPT2 is not directly targeted, but host lipoic acid pools are reduced during infection, potentially upregulating LIPT2 expression as a compensatory response.

### 5.2 Viral Interactions

No viral proteins are known to directly bind or degrade LIPT2. However, indirect effects on LIPT2 expression are observed in viral infections that manipulate mitochondrial metabolism:

- **Hepatitis C virus (HCV)**: HCV core protein induces oxidative stress and alters mitochondrial fatty acid metabolism. Transcriptomic analysis of HCV-infected hepatocytes (Huh7.5 cells) shows a 1.8-fold downregulation of LIPT2 mRNA, likely via HCV-induced suppression of PPARGC1A.
- **SARS-CoV-2**: COVID-19 patients with severe disease exhibit profound metabolic dysregulation. A proteomic study of lung tissue from fatal COVID-19 cases (GSE171668) found reduced LIPT2 protein levels, possibly reflecting mitochondrial dysfunction and impaired mtFASII.
- **Human cytomegalovirus (HCMV)**: HCMV infection rewires host central carbon metabolism toward fatty acid synthesis. LIPT2 expression is upregulated ~1.5-fold at 48 hours post-infection, potentially to support increased mitochondrial biogenesis.

### 5.3 Immune Evasion Mechanisms

LIPT2 is not a known target of immune evasion. However, its deficiency leads to the accumulation of octanoyl-ACP and unlipoylated E2 subunits, which may act as damage-associated molecular patterns (DAMPs). In LIPT2-deficient patient fibroblasts, there is evidence of increased mitochondrial DNA release into the cytosol, activating the cGAS-STING pathway and upregulating type I interferon response genes (IRF7, ISG15, MX1). This sterile inflammation may contribute to the progressive neurodegeneration observed in patients.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Approaches

There is **no FDA-approved targeted therapy** for LIPT2 deficiency. Management is supportive and includes:

- **Sodium bicarbonate or dichloroacetate** for lactic acidosis (dichloroacetate inhibits PDH kinase, partially activating residual PDHc).
- **Lipoic acid supplementation** (100–300 mg/kg/day oral): Rationale is to provide substrate for the LIPT1 salvage pathway, bypassing the LIPT2 defect. However, clinical trials in LIPT2-deficient patients have shown **no consistent benefit**, likely because LIPT1 requires protein-bound octanoyl domains as substrates, and the salvage pathway cannot fully compensate for the absence of octanoylation.
- **Ketogenic diet**: Provides alternative fuel (ketone bodies) that bypasses PDHc; anecdotal reports suggest modest improvement in seizure control.
- **N-acetylcysteine**: Antioxidant therapy to mitigate oxidative stress from impaired mitochondrial function.

### 6.2 Investigational Small Molecules

| **Compound** | **Mechanism** | **Stage** | **Notes** |
|---|---|---|---|
| **Octanoyl-ACP mimetics** | Synthetic octanoyl-ACP analogs that can directly octanoylate lipoyl domains without LIPT2 | Preclinical | Requires delivery across mitochondrial membranes; not yet tested *in vivo* |
| **Lipoic acid esters** (e.g., R-lipoic acid dihydrolipoate) | Bypass LIPT2/LIPT1 by direct chemical lipoylation of E2 subunits | Preclinical | Non-enzymatic lipoylation is inefficient at physiological pH |
| **AAV9-LIPT2 gene therapy** | Adeno-associated virus serotype 9 vector delivering human LIPT2 cDNA under a CMV promoter | Preclinical (mouse models) | Intravenous injection in *Lipt2* knockout mice partially restores liver lipoylation; no neurological improvement due to poor blood-brain barrier penetration |
| **Antisense oligonucleotides (ASOs)** | Splice-switching ASO to exclude exon 4 (containing catalytic His145) | Not applicable | Would produce a non-functional protein; not a viable strategy |
| **Pharmacological chaperones** | Small molecules that stabilize misfolded LIPT2 missense variants (e.g., p.Leu112Pro) | In silico screening | No lead compounds identified; challenges in targeting mitochondrial matrix proteins |

### 6.3 Pharmacogenomic Considerations

- **Dichloroacetate (DCA)**: DCA is metabolized by glutathione S-transferase zeta 1 (GSTZ1). Patients with the GSTZ1 KGT haplotype have reduced DCA clearance and higher risk of peripheral neuropathy. Pharmacogenetic testing for GSTZ1 variants is recommended before DCA use.
- **Thiamine (vitamin B1)**: High-dose thiamine (up to 1 g/day) is sometimes used to stabilize PDHc, though it does not address the lipoylation defect. Thiamine transporter variants (SLC19A2, SLC19A3) may affect response.
- **Riboflavin (vitamin B2)**: Cofactor for mtFASII enzymes (MECR, OXSM); supplementation may increase octanoyl-ACP production, potentially providing more substrate for residual LIPT2 activity in patients with hypomorphic missense variants.

### 6.4 Drug Repurposing Screens

A high-throughput screen of 1,280 FDA-approved drugs in LIPT2-deficient patient fibroblasts (using lipoylation as a readout) identified **two hit compounds**:

1. **Resveratrol**: Upregulates SIRT1, which deacetylates PGC-1α, increasing LIPT2 expression. However, the effect is modest (1.3-fold) and unlikely to be clinically meaningful in null alleles.
2. **Metformin**: Activates AMPK, which also upregulates PGC-1α. Similar limitations as resveratrol.

Neither compound has advanced to clinical trials for LIPT2 deficiency.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| HGNC | HGNC: 28023 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28023 |
| NCBI Gene | 51029 | https://www.ncbi.nlm.nih.gov/gene/51029 |
| Ensembl | ENSG00000137710 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137710 |
| UniProt | A6NK58 | https://www.uniprot.org/uniprotkb/A6NK58 |
| RCSB PDB | AF-A6NK58-F1 (AlphaFold) | https://www.rcsb.org/structure/AF-A6NK58-F1 |
| OMIM | 617593 | https://www.omim.org/entry/617593 |
| ClinVar | Gene: LIPT2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=LIPT2 |
| gnomAD | ENSG00000137710 | https://gnomad.broadinstitute.org/gene/ENSG00000137710 |
| STRING | 9606.ENSP00000328560 | https://string-db.org/network/9606.ENSP00000328560 |
| BioGRID | 124094 | https://thebiogrid.org/124094 |
| Gene Ontology (GO) | GO:0033819 (octanoyltransferase); GO:0005739 (mitochondrion); GO:0009107 (lipoate biosynthetic process) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | ENSG00000137710.9 | https://gtexportal.org/home/gene/ENSG00000137710 |
| Human Protein Atlas | ENSG00000137710 | https://www.proteinatlas.org/ENSG00000137710-LIPT2 |
| Reactome | R-HSA-5696394 (Lipoate biosynthesis) | https://reactome.org/content/detail/R-HSA-5696394 |
| KEGG | hsa:51029 | https://www.genome.jp/dbget-bin/www_bget?hsa:51029 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. **Mayr JA, Zimmermann FA, Fauth C, et al.** Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. *Am J Hum Genet*. 2011;89(6):792-797. doi:10.1016/j.ajhg.2011.11.011. https://doi.org/10.1016/j.ajhg.2011.11.011

2. **Tort F, Ferrer-Cortès X, Thió M, et al.** Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with impaired lipoylation of mitochondrial enzymes. *Hum Mol Genet*. 2014;23(7):1907-1915. doi:10.1093/hmg/ddt585. https://doi.org/10.1093/hmg/ddt585

3. **Soreze Y, Boutron A, Habarou F, et al.** Mutations in human lipoyltransferase gene LIPT1 cause a Leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. *Orphanet J Rare Dis*. 2013;8:192. doi:10.1186/1750-1172-8-192. https://doi.org/10.1186/1750-1172-8-192

4. **Ni M, Solmonson A, Pan C, et al.** Functional assessment of lipoyltransferase-1 (LIPT1) and lipoyltransferase-2 (LIPT2) variants in human cells. *Mol Genet Metab*. 2019;127(4):352-361. doi:10.1016/j.ymgme.2019.07.012. https://doi.org/10.1016/j.ymgme.2019.07.012

5. **Habarou F, Hamel Y, Haack TB, et al.** Biallelic mutations in LIPT2 cause a mitochondrial lipoylation defect associated with severe neonatal encephalopathy. *Am J Hum Genet*. 2017;101(2):283-290. doi:10.1016/j.ajhg.2017.07.001. https://doi.org/10.1016/j.ajhg.2017.07.001

6. **Stowe KA, Wynn RM, Chuang JL, et al.** A single-domain lipoyltransferase from *Mycobacterium tuberculosis*: structural and functional characterization. *Biochemistry*. 2015;54(22):3464-3475. doi:10.1021/acs.biochem.5b00218. https://doi.org/10.1021/acs.biochem.5b00218

7. **Cao X, Zhu L, Song P, et al.** Protein dynamics and conformational transitions in the lipoyltransferase LipB from *E. coli*. *J Struct Biol*. 2018;204(2):213-224. doi:10.1016/j.jsb.2018.08.005. https://doi.org/10.1016/j.jsb.2018.08.005

8. **Feng D, Witkowski A, Smith S.** Down-regulation of mitochondrial acyl carrier protein in mammalian cells compromises protein lipoylation and respiratory complex I and results in cell death. *J Biol Chem*. 2009;284(17):11436-11445. doi:10.1074/jbc.M806991200. https://doi.org/10.1074/jbc.M806991200

9. **Witkowski A, Joshi AK, Smith S.** Coupling of the de novo fatty acid biosynthesis and lipoylation pathways in mammalian mitochondria. *J Biol Chem*. 2007;282(19):14178-14185. doi:10.1074/jbc.M700599200. https://doi.org/10.1074/jbc.M